Hua Medicine Announces the Drug Manufacturing Permit Granted for Dorzagliatin
SHANGHAI, CHINA, Oct 14, 2020 - (ACN Newswire) - Hua Medicine (the "Company", Stock Code: 2552.HK) announces that, after review and on-site verification under the Marketing Authorization Holder ("MAH") system, the Company has obtained the drug manufacturing permit for dorzagliatin, its investigational first-in-class drug, issued by the Shanghai Municipal Drug Administrative Bureau.
Since the beginning of this year, Hua Medicine has successfully completed two critical milestones for marketing registration, SEED (HMM0301), the Phase III clinical trial of dorzagliatin monotherapy in drug naive patients with Type 2 diabetes (T2D) and DAWN (HMM0302), the metformin combination clinical trial in T2D patients inadequately glycemic controlled with metformin. The results of the studies showed that, during the relevant treatment period, dorzagliatin has demonstrated its long-lasting efficacy and favorable safety profiles, and can improve the pancreatic beta-cell functions, promote early-phase insulin secretion and reduce insulin resistance, which is expected to fundamentally treat diabetes. On August 17, Hua Medicine and Bayer announced the establishment of their strategic partnership and concluded a cooperative agreement on the commercialization of dorzagliatin in China. Hua Medicine will be responsible for the clinical development, registration, product supply and distribution, whilst Bayer, as the exclusive promotion service provider for the product in China, will be responsible for its marketing, promotion and medical education activities in China. Hua Medicine will receive an upfront payment of RMB 300 million and additional payments could reach up to RMB 4.18 billion if certain milestones are met. The grant of the drug manufacturing permit will further accelerate the dorzagliatin New Drug Application (NDA) process of Hua Medicine, facilitate the commercial production and supply of the drug upon the product launch and lay a solid foundation for the expected increase of production capacity in the future.
According to the newly revised Drug Administration Law and Administrative Measures for the Supervision and Administration of Drug Manufacturing, the MAH, as the main party engaged in drug manufacturing, must obtain the drug manufacturing permit, whether it manufactures drugs by itself or entrusts the manufacturing to a third party. Hua Medicine is among the first group of biotechnology companies that have obtained the drug manufacturing permit since the implementation of the new Drug Administration Law on December 1, 2019. The grant of the drug manufacturing permit indicates that Hua Medicine and its CMOs have completed the core work related to commercialization of the drug. After dorzagliatin is approved for commercialization, Hua Medicine may entrust the manufacturing of dorzagliatin to the current CMOs to prepare for product launch. At the same time, the drug manufacturing permit is a requisite for submitting the NDA, which will help speed up the approval process for new drugs.
As one of the first batch of MAH enterprises in China, Hua Medicine has established management systems for drug safety/pharmacovigilance and pharmaceutical quality that are in line with its responsibilities as a MAH and also comply with international and domestic standards. The drug manufacturing permit granted for dorzagliatin is a recognition of Hua Medicine's management capabilities and management practices. It also means that Hua Medicine, who will become a drug marketing and registration applicant and a drug marketing license holder, fully possesses the compliant, high-quality and efficient management systems and management capabilities necessary for drug life-cycle quality management, entrusted production management, drug safety and pharmacovigilance management, risk management, post-market traceability system and liability compensation.
"The drug manufacturing permit granted for dorzagliatin marks an important milestone of Hua Medicine. It is also a full recognition of the principle of 'high standards and high quality to create high value' that Hua Medicine has always adhered to. Hua Medicine will continue to work with partners in the fields of clinical trial, drug production and commercialization to bring dorzagliatin, the first-in-class drug for diabetes, to patients in the world as soon as possible," said Dr. Li CHEN, CEO of Hua Medicine.
Dorzagliatin is an investigational first-in-class, dual-acting glucokinase activator, designed to control the progressive, degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 diabetes. By addressing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired glucose homeostasis state of patients with Type 2 diabetes and serve as a first-line standard-of-care therapy for the treatment of the disease, or as a cornerstone therapy when taken in combination with currently approved anti-diabetes drugs.
About Hua Medicine
Hua Medicine is a leading, clinical-stage innovative drug development company in China focused on developing novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua Medicine advanced a first-in-class oral drug for the treatment of T2DM into NDA-enabling stage and is currently evaluating the therapy in adults with diabetes in two Phase III trials in China and various earlier stage clinical trials in China and the United States. Dorzagliatin has achieved its primary endpoint in both of its Phase III monotherapy and combination trials in China over the 24-week trial period, and completed its 52-week Phase III monotherapy trial. The Company has initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine is working closely with disease experts and regulatory agencies in China and across the world to advance diabetes care solutions for patients worldwide.
For more information
Email: [email protected]
Email: [email protected]
Issued by Porda Havas International Finance Communications Group for and on behalf of Hua Medicine. For further information, please contact:
Mr. Bunny Lee +852 3150 6707 [email protected]
Ms. Louisa Chen +86 75523807432 [email protected]
Ms. Cecilia Chen +852 3150 6733 [email protected]
Ms. Catherine Yu +852 3150 6729 [email protected]
Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
Copyright ©2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
More Latest Release >>
Mitsubishi Shipbuilding Receives Approval in Principle for LNG Fuel Gas Supply System from Bureau Veritas
Oct 19, 2020 19:07 JST
Supercomputer Fugaku Wins the "Minister of Internal Affairs and Communications Award" at CEATEC 2020 ONLINE
Oct 19, 2020 18:49 JST
Toyota's GR Yaris Makes Its Dynamic Debut at the Goodwood Speedweek
Oct 19, 2020 18:41 JST
Fujitsu Commences Full-Scale Operation of HOKUSAI - SailingShip, RIKEN's New Data Science Infrastructure
Oct 19, 2020 10:39 JST
New ECLIPSE CROSS Reveals Radical New Styling and Expands Plug-In Hybrid Option
Oct 19, 2020 09:45 JST
Honda Announces Completion of the Tender Offer for Shares in Keihin, Showa and Nissin
Oct 16, 2020 17:16 JST
Showa Denko Markets PNVA(TM) 'GE191 Series' for Use as Binder to Form Heat-resisting Ceramic Layer in Separators for LIBs
Oct 16, 2020 16:00 JST
Eisai: Supplementary New Drug Applications for Anti-Epileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures
Oct 16, 2020 13:44 JST
Fujitsu Verifies Effectiveness of Private 5G in Manufacturing Sites in Collaboration with Microsoft Japan
Oct 16, 2020 11:33 JST
Hitachi Acquired Additional Shares to Hold Majority of Shares of Yungtay, Elevator Company Based in Taiwan
Oct 15, 2020 17:41 JST
Mitsubishi Power Signs MOU with Indonesia's PLN Group and Bandung Institute of Technology (ITB) on Joint Policy Proposal to Promote Biomass Co-firing at Thermal Power Plants in Indonesia
Oct 15, 2020 12:06 JST
Hitachi ABB Power Grids Wins $6.6 Million Projects to Digitalize High-Speed Rail in the UK
Oct 14, 2020 17:48 JST
MHI Group Undertakes Investment in HydrogenPro of Norway, Leading Producer of Advanced Electrolyzers
Oct 14, 2020 15:33 JST
Toyota: Launch of a Preparatory Committee for "Japan Hydrogen Association (JH2A)"
Oct 14, 2020 14:06 JST
Fujitsu Accelerates Digital Transformation at Mizuho Bank Branches with Innovative Tablet Solution
Oct 14, 2020 12:58 JST
Fujitsu and PeptiDream Achieve Milestone in Joint Research for Peptide Drug Candidates with High-Speed, High-Precision Exploration Technology
Oct 13, 2020 17:04 JST
Fujitsu Commences Joint Research with World-Leading Institutions for Innovations in Quantum Computing
Oct 13, 2020 16:41 JST
Hitachi ABB Power Grids and Tensio TN AS to deliver Norway's First Fully Digital, Eco-efficient Substation
Oct 13, 2020 16:25 JST
Toyota: Heavy-Duty Fuel Cell Electric Truck Verification Tests to Start in Spring 2022
Oct 13, 2020 15:22 JST
DENSO Developed New Generation Battery-Monitoring Integrated Circuit for Lithium-ion Batteries, a Key component of Battery ECUs
Oct 13, 2020 11:54 JST